Senseonics Holdings, Inc. (SENS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Senseonics is a medical technology company focused on implantable continuous glucose monitoring (CGM) systems, specifically the Eversense E3 and Eversense 365. The company is in the early stages of commercialization, transitioning commercial operations from its partner, Ascensia Diabetes Care Holdings AG, back to Senseonics, with the transition expected to begin January 1, 2026. A 1-for-20 reverse stock split was effected on October 17, 2025, and all historical share data in this filing has been adjusted to reflect this split.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $8.1 million | $4.3 million | $21.0 million | $14.2 million |
| Gross Profit | $3.5 million | ($4.1 million) | $8.1 million | ($3.4 million) |
| Gross Margin | 42.8% | (95.0%) | 38.5% | (24.1%) |
| Operating Loss | ($19.6 million) | ($22.8 million) | ($47.4 million) | ($60.6 million) |
| Net Loss | ($19.5 million) | ($24.0 million) | ($48.3 million) | ($63.1 million) |
| Cash & Equivalents | $34.5 million | $74.6 million | As of Sept 30, 2025 | |
| Short-term Investments | $76.5 million | $0 | As of Sept 30, 2025 | |
| Total Liquidity | $111.0 million | $74.6 million | As of Sept 30, 2025 | |
| Long-term Debt | $35.3 million | $34.7 million | As of Sept 30, 2025 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 89.9% year-over-year for Q3 2025, driven by growth in the U.S. consignment program and demand for the 365-day Eversense product. U.S. revenue now represents 79.3% of total revenue.
- Gross Margin Improvement: The company returned to profitability on a gross basis in Q3 2025. This improvement is attributed to the absence of $4.8 million in one-time inventory write-offs incurred in Q3 2024 during the transition from Eversense E3 to Eversense 365, as well as favorable margins on the new 365-day product.
- Expense Management: R&D expenses decreased by $2.8 million in Q3 2025 compared to the prior year, primarily due to the completion of Eversense 365 clinical trials and reduced headcount. Conversely, SG&A expenses increased by $7.1 million, driven by $4.7 million in increased promotional expenses for direct-to-consumer marketing and higher sales commissions to Ascensia.
- Debt Repayment: The company fully repaid its $20.4 million 2025 Notes in January 2025, significantly reducing interest expense.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the twelve months following the issuance of these financial statements. This is due to the capital requirements needed to assume full commercialization responsibilities from Ascensia and the need to meet debt covenants.
- Commercial Transition: A Memorandum of Understanding (MOU) was signed with Ascensia to transfer commercial operations back to Senseonics, effective January 1, 2026. This transition will require significant working capital to build internal sales and marketing infrastructure.
- Financing Activities: In May 2025, the company raised approximately $72.2 million in net proceeds through a Public Offering and a Private Placement with Abbott Laboratories. In August 2025, an at-the-market (ATM) sales agreement was established with TD Cowen for up to $100 million.
- Debt Facility: The Loan and Security Agreement with Hercules Capital was amended in September 2025, increasing the total commitment from $50 million to $100 million. The facility includes performance covenants commencing in 2026.
- Legal Proceedings: The company is involved in a patent infringement lawsuit filed by Cellspin Soft, Inc. The proceedings are currently stayed pending the resolution of Inter Partes Review challenges at the USPTO.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $111 million liquidity position against the projected cash burn required to build a commercial sales force and meet debt covenants over the next 12 months.
- Transition Costs: Monitor the finalization of the definitive agreement with Ascensia to understand the specific costs and liabilities Senseonics will assume upon taking over commercial operations.
- Revenue Concentration: Assess the risk associated with Ascensia, which accounted for 56% of revenue in the first nine months of 2025, and the impact of the upcoming transition on this revenue stream.
- Debt Covenants: Review the specific performance milestones required under the Amended Loan and Security Agreement to avoid default, particularly the revenue targets starting in 2026.
- Reverse Stock Split Impact: Evaluate the post-split trading liquidity and market price stability following the 1-for-20 reverse stock split effective October 17, 2025.